Technology Available

5. Salient Features/Advantages: ü First-in-class peptide based inhibitor of α-synuclein aggregation is discovered. ü The molecule inhibits α-Synuclein aggregation in sub-stoichiometry concentrations. ü Another cyclic-derivative of the identified also inhibited α-synuclein amyloid aggregation. ü The identified peptide improved locomotory activity in C. elegans model of PD ü The identified peptide improved locomotory activity in mice models of PD. ü The peptide is known to cross blood brain barrier. ü The peptide reduces the pathogenic aggregate burden in mice brain. ü The peptide reduces Lewy neurites burden, reduces neuroinflammation, improves tyrosine hydroxylase expression in mice brain.